secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-07-15T23:59:59+00:00
Accession:  0000950170-24-083386
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo positive Phase 1/2 data for LX2006 in FA cardio: LVMI -11.4% at 12mo, safe
--------------------------------------------------------------------------------

- Mean LVMI reduction 11.4% at 12 months and 18.3% at 18 months in patients with elevated baseline LVMI.
- 75% of elevated-baseline patients achieved >10% LVMI reduction at 12 months.
- hsTnI, a myocardial injury biomarker, reduced 53.3% on average at 12 months (n=5).
- Frataxin expression increased post-treatment in all evaluable biopsies; no treatment-related SAEs.
- Cohort 3 dosing started (1.2x10^12 vg/kg); DSMB endorsed progression; 13 total participants dosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024083386/0000950170-24-083386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024083386/lxeo-20240715.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-083386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer